CurrentUnitedHealthcarePolicy N/A

Medication prior authorization for systemic lupus nephritis therapy

Form/criteria governing prior authorization and re-authorization requests for a medication used to treat active systemic lupus nephritis; intended for prescribers and pharmacy benefit reviewers processing UnitedHealthcare authorization requests.

Policy Summary

PayerUnitedHealthcare

PolicyMedication prior authorization for systemic lupus nephritis therapy

Policy CodePolicy N/A

Change TypeNo material change

Effective DateN/A

Next Review DateN/A

Key ActionProvider must complete the prior authorization form questions (1-12 for initial authorization, 13-15 for re-authorization) and attach current progress notes as required.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

15total auth items

12initial auth

3re-auth

1-365therapy length options (days)

Coverage Criteria

Initial Authorization

Covered when ALL of the following are met and documented on the prior authorization form:

Initial authorization: 1. Diagnosis of active systemic lupus nephritis documented on the form; 2. ISN/RPS biopsy‑proven disease documented; 3. Urine protein to creatinine ratio (UPCR) value provided; 4. No hypersensitivity to any component of the medication; 5. Medication is not being administered with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin); 6. No severe hepatic impairment; 7. Beneficiary is concomitantly receiving background immunosuppressive therapy (except cyclophosphamide); 8. Baseline blood pressure provided; 9. Baseline estimated glomerular filtration rate (eGFR) provided; 10. Plan to assess renal function (eGFR) at regular intervals; 11. Medication prescribed by or in consultation with a rheumatologist

Answers are captured via checklist items 1-12 on the form.

Re-authorization

Covered for re-authorization when ALL of the following are met and documented:

Re-authorization: 13. Beneficiary continues to meet the initial authorization criteria (questions 1-12); 14. Demonstrated disease improvement and/or stabilization or improvement in slope of decline; 15. No treatment‑restricting adverse effects (e.g., hypertension, neurotoxicities, hyperkalemia)

Policy Summary

PayerUnitedHealthcare

PolicyMedication prior authorization for systemic lupus nephritis therapy

Policy CodePolicy N/A

Change TypeNo material change

Effective DateN/A

Next Review DateN/A

Key ActionProvider must complete the prior authorization form questions (1-12 for initial authorization, 13-15 for re-authorization) and attach current progress notes as required.

SourceLink

On This Page

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

The form makes several items mandatory for the medical necessity determination; missing or incomplete responses may result in denial or delayed review. Examples called out on the form include absence of ISN/RPS biopsy-proven documentation, failure to provide a baseline UPCR value, or lack of documentation that the patient is on appropriate background immunosuppressive therapy (except cyclophosphamide).

For re-authorization, the form requires attachment of current progress notes documenting disease status and clinical response. Failure to attach these notes, or to demonstrate continued meeting of initial criteria, documented improvement/stabilization, and absence of treatment-restricting adverse effects, may preclude continued coverage.

Provider Actions & Submission Requirements

Prior Authorization

Prior Authorization Required

Prior authorization form completion required — Provider must complete the initial authorization questions (items 1-12) on the PA form. This includes: confirmation of active systemic lupus nephritis diagnosis, documentation of ISN/RPS biopsy-proven diagnosis (if applicable), urine protein to creatinine (UPCR) value, baseline blood pressure and eGFR, current concomitant background immunosuppressive therapy (excluding cyclophosphamide), assessment plans for renal function monitoring, and prescriber specialty/consultation information.

Provider must complete all initial authorization items 1–12 on the PA form
Include prescriber NPI, contact/fax, and prescriber signature and date

Step Therapy

Step therapy — the PA form does not specify an explicit step sequence or prior-therapy requirements on the form itself. If a plan-level step therapy policy applies, follow the payer-specific step requirements; otherwise document rationale for current therapy on the PA form.

Form contains no explicit steps to complete before approval — check payer clinical policy for any external step requirements
If applicable, document prior therapies and reasons for selecting current agent on the PA form

Denial Risk

Denial Risk — Missing or Incomplete Documentation

Possible triggers for denial — missing or incomplete documentation identified on the PA form or attachments may lead to denial. Common triggers include absence of biopsy-proven ISN/RPS diagnosis when required, missing UPCR value, lack of documentation of background immunosuppressive therapy (excluding cyclophosphamide), no plan for renal function monitoring, missing prescriber specialty/consultation information, missing prescriber signature/date, or failure to attach current progress notes showing disease status and response.

Missing ISN/RPS biopsy documentation when requested
UPCR value not provided
No documentation of background immunosuppressive therapy (if applicable)
No documentation of planned renal function (eGFR) monitoring
Prescriber signature or date missing on the form
Current progress notes not attached for re-authorization

Documentation Required

Required documentation to attach — Attach current progress notes that document diagnosis, baseline labs (including UPCR and eGFR), baseline vitals (blood pressure), background immunosuppressive medications, treatment response for re-authorization, and any adverse events. Prescriber signature and date are mandatory on the form.

Attach current progress notes documenting disease status and clinical response
Include baseline UPCR and eGFR values and plan for monitoring
Document background immunosuppressive therapy (exclude cyclophosphamide if applicable)
Include prescriber signature and date (mandatory)

Definitions

ISN/RPS biopsy-proven — definition and reference as requested on the form

Definition requested on form'International Society of Nephrology/Renal Pathology Society (ISN/RPS) biopsy-proven' — renal biopsy documentation per ISN/RPS criteria is required to confirm diagnosis

Form locationInitial authorization questions (question 2) requests ISN/RPS biopsy-proven status

RelevanceRequired element for initial authorization; absence may trigger denial or non-coverage

UPCR — urine protein to creatinine ratio requested as baseline disease activity metric

Metric requestedUrine protein to creatinine ratio (UPCR) — requested as baseline disease activity metric (question 3 on the form)

UseUsed to document baseline renal disease activity for authorization and re‑authorization assessments

OpenPayer

Medication prior authorization for systemic lupus nephritis therapy

Coverage Criteria

Coding and Therapy Duration

Provider Actions & Submission Requirements

Background

Definitions